Literature DB >> 10651112

Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761).

S Hoyer1, H Lannert, M Nöldner, S S Chatterjee.   

Abstract

The standardized extract EGb 761 from the dried green leaves of Ginkgo biloba is a complex mixture of ingredients with an uniquely broad spectrum of pharmacological activities on the central nervous system e.g. in memory enhancing properties and in the regulation of cerebral glucose/energy metabolism. To test these effects on both behavioral and metabolic brain parameters, the animal model of intracerebroventricular (i.c.v.) streptozotocin (STZ) treatment was used. To quantify the experimental data more precisely, animals that were good performers were separated from poor performers by means of the holeboard test before i.c.v. administration of STZ. Good performers only were considered for the study. After a 1-week training period on the holeboard improvement was seen in all animals in learning, memory and cognition, and the improvement was maintained over the investigation period of 12 weeks in the control group. In this group, the energy pool in the cerebral parietotemporal cortex was found to be large and the energy turnover high. After triplicate i.c.v. STZ injection, working memory (WM), reference memory (RM), and passive avoidance (PA) behavior fell off and continued to deteriorate throughout the investigation period. Otherwise there were no significant differences in locomotor activity, excluding the possibility that activity per se might have contributed to the behavioral abnormalities. These were accompanied by a permanent deficit in cerebral energy metabolism. The ongoing deterioration in behavior and the maintained deficit in cerebral energy metabolism occurring after a triplicate i.c.v. STZ injection were significantly slowed down by EGb761. The deficits in learning, memory and cognition were partially compensated, and the disturbances in cerebral energy metabolism returned to almost completely normal values. These findings underscore the beneficial effect of EGb761 that had been reported in dementia disorders.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10651112     DOI: 10.1007/s007020050232

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  31 in total

1.  Ginkgo biloba extracts EGb 761 and bilobalide increase NADH dehydrogenase mRNA level and mitochondrial respiratory control ratio in PC12 cells.

Authors:  Elisabetta A Tendi; Francesca Bosetti; S Fenella Dasgupta; Anna Maria Giuffrida Stella; Katy Drieu; Stanley I Rapoport
Journal:  Neurochem Res       Date:  2002-04       Impact factor: 3.996

Review 2.  Diabetes type II: a risk factor for depression-Parkinson-Alzheimer?

Authors:  Peter Riederer; Jasmin Bartl; Gerd Laux; Edna Grünblatt
Journal:  Neurotox Res       Date:  2010-06-15       Impact factor: 3.911

Review 3.  Brain metabolic dysfunction at the core of Alzheimer's disease.

Authors:  Suzanne M de la Monte; Ming Tong
Journal:  Biochem Pharmacol       Date:  2013-12-28       Impact factor: 5.858

4.  Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease.

Authors:  Ming Tong; Alexander Neusner; Lisa Longato; Margot Lawton; Jack R Wands; Suzanne M de la Monte
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 5.  Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art.

Authors:  Suzanne M de la Monte
Journal:  Expert Opin Drug Deliv       Date:  2013-11-12       Impact factor: 6.648

Review 6.  Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis.

Authors:  Suzanne M de la Monte; Lisa Longato; Ming Tong; Jack R Wands
Journal:  Curr Opin Investig Drugs       Date:  2009-10

Review 7.  Effects of Ginkgo biloba in dementia: systematic review and meta-analysis.

Authors:  Stefan Weinmann; Stephanie Roll; Christoph Schwarzbach; Christoph Vauth; Stefan N Willich
Journal:  BMC Geriatr       Date:  2010-03-17       Impact factor: 3.921

8.  Alzheimer's disease is type 3 diabetes-evidence reviewed.

Authors:  Suzanne M de la Monte; Jack R Wands
Journal:  J Diabetes Sci Technol       Date:  2008-11

Review 9.  What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research.

Authors:  Melita Salkovic-Petrisic; Ana Knezovic; Siegfried Hoyer; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2012-08-12       Impact factor: 3.575

10.  Nitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment.

Authors:  Suzanne M de la Monte; Ming Tong; Margot Lawton; Lisa Longato
Journal:  Mol Neurodegener       Date:  2009-12-24       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.